

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :	A1	(11) International Publication Number:	WO 96/19186
(A61K 7/043, 9/70, 31/095)		(43) International Publication Date:	27 June 1996 (27.06.96)
(21) International Application Number:	PCT/US95/15729	(81) Designated States:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).
(22) International Filing Date:	5 December 1995 (05.12.95)	(20) Priority Data:	
08/361,413	22 December 1994 (22.12.94) US	(71) Applicant:	JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. [US/US]; Grandview Road, Skillman, NJ 08558 (US).
(72) Inventors:	SUN, Ying; 19 Woodville Terrace, Somerville, NJ 08876 (US). LIU, Jue-Chen; 29 VanBolton Road, Neshanick, NJ 08853 (US). KIMBLETON, Elizabeth, S.; 187 Sayre Drive, Princeton, NJ 08540 (US). WANG, Jonas, C., T.; 23 Ellsworth Drive, Robbinsville, NJ 08691 (US).	(74) Agents:	CIAMPORCERO, Audley, A. et al.; One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).

(54) Title: ANTIFUNGAL TREATMENT OF NAILS

(57) Abstract

There is disclosed a method for the treatment of fungal diseases in nails, which comprises the topical administration to the nail and, if desired, also to the surrounding skin, of (1) a sulphydryl containing amino acid or a derivative thereof, the pharmaceutically acceptable salts or esters thereof, or stereoisomers thereof, (2) urea, (1) and (2) being administered in an amount sufficient to enhance the permeation of antifungal drugs through nail tissue, either prior to or, preferably, concurrently with the topical administration to the nail of (3) an effective amount of an antifungal drug. There is also disclosed a bandage adapted for the topical administration of medication to the nail, said bandage comprising a T-shaped adhesive backing, and a flexible pad having an impervious backing and a nail-shaped cavity backed by said impervious backing, wherein said nail-shaped cavity contains absorptive means having absorbed therein urea and a sulphydryl containing amino acid or a derivative thereof, a pharmaceutically acceptable salt or ester thereof, or a stereoisomer thereof.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

ANTIFUNGAL TREATMENT OF NAILS

The invention relates to a method for the topical treatment of fungal diseases in nails, and more particularly, to a composition and a method for enhancing the permeation rate of antifungal agents in nails. The invention also relates to a bandage adapted for use with the method of the invention.

Background of the Invention

10

Although significant progress has been made in the development of antifungal drugs, nail fungal infection (e.g., onychomycosis) remains a disease most difficult to treat. The target sites for the treatment of onychomycosis reside in the nail plate, nail bed and nail matrix (see Figure 1). Topical treatment has not been effective because antifungal drugs cannot readily penetrate the nail plate to reach the infection sites under the nail. Oral administration of antifungal drugs is the only effective way to treat onychomycosis, which has limited the use of some of the more potent antifungal drugs such as itraconazole and ketoconazole because of concern for possible side effects. It has been shown, however, that if the nail barrier can be overcome or eliminated, topical antifungal drug treatment can be effective. For example, both miconazole and ketoconazole were demonstrated to be effective in topically treating onychomycosis after nail avulsion. There is a need for a methodology for topical nail fungal treatment that does not require removal of the nail. Such topical treatment would then permit the use of the more potent antifungal drugs in the treatment of fungal-infected nails.


The nail plate is too thick and too dense for drugs to penetrate at a practical rate. Although nail is similar to stratum corneum of the skin in that it is derived from epidermis, it is mainly composed of hard keratin (highly disulfide-linked) and is approximately 100-fold thicker than stratum corneum. In order to deliver a sufficient amount of drug into

the nail plate, the permeability of the nail plate to the drug needs to be enhanced. The permeation-related properties of the nail differ from those observed in stratum corneum primarily in three respects: (a) the total lipid content of the nail is much less than the lipid content of stratum corneum; (b) the nail has a high sulphur content (cystine) in its hard keratin domain whereas the stratum corneum does not; (c) under average conditions, the nail contains much less water than the stratum corneum.


10

The chemical composition of nail and experimental evidence indicate that the aqueous pathway plays a dominant role in drug penetration into nail. Water is the principal plasticizer for the nail. Upon being hydrated, hard nail plates become softer and more flexible. Nail hydration is influenced by many factors, such as solution pH and certain chemicals. Keratolytic agents, such as urea and salicylic acid are often used to soften nail plates. Urea and a combination of urea and salicylic acid were reported to be used for nonsurgical avulsion of nail dystrophies in clinical studies prior to topical treatment of onychomycosis with satisfactory results.

Nail plates have high sulphur content in the form of disulfide bonds. Certain reducing agents, e.g., cysteine or a derivative thereof, can break the disulfide bond in keratin to increase the ability of the nail to hydrate. The chemical reaction that occurs between the disulfide bonds in nail keratin and a thiol-containing compound (in this case, cysteine) is shown in the following scheme:



30



This invention provides a delivery means for topical treatment of fungal diseases of the nail which delivers an effective dose of drug to (a) the diseased nail plate (and consequently, the underlying nail bed), of which the hydration capability has been significantly increased to enhance drug permeability (nail route); and (b) the surrounding skin tissues, including nail bed and matrix via the eponychium and hyponychium (skin route - see Figure 1).

10

Brief Summary of the Invention

The invention provides a method for the treatment of fungal diseases in nails, which comprises the topical administration to the nail and, if desired, also to the surrounding skin, of (1) a sulfhydryl containing amino acid or a derivative thereof, the pharmaceutically acceptable salts or esters thereof, or stereoisomers thereof, (2) urea, (1) and (2) being administered in an amount sufficient to enhance the permeation of antifungal drugs through nail tissue, either prior to or, preferably, concurrently with the topical administration to the nail of (3) an effective amount of an antifungal drug. The invention also provides a composition comprising (1), (2) and (3), as described above.

25

The invention further provides a bandage adapted for the topical administration of medication to the nail, said bandage comprising a T-shaped adhesive backing, and a flexible pad having an impervious backing and a nail-shaped cavity backed by said impervious backing, wherein said nail-shaped cavity contains absorptive means having absorbed therein urea and a sulfhydryl containing amino acid or a derivative thereof, a

pharmaceutically acceptable salt or ester thereof, or a stereoisomer thereof.

The Prior Art

5

The reduction reaction between keratin disulfide bonds and thioglycolates are frequently utilized in the cosmetic industry, e.g., for cold waving and depilatory of hair, and enhancing cosmetic appearance of the nail.

10

Olthoff et al., in EP 440298 A1, disclose the use of sulfur-containing amino acid derivatives in topical preparations for treatment of nail diseases such as onychomycosis.

15

Kawase et al (EP 472858 A2 4 Mar 1992) describe a hair treatment composition containing siloxanes and penetration enhancers such as ammonium thioglycolate, which gives the treated hair a good gloss and a reduced number of hair splits.

20

Puri (WO 8600013 A1 3 Jan 1986) discloses that the condition of hair, skin and nails is improved by treatment with an aqueous ammonium thioglycolate solution, followed by treatment with a protein hydrolyzate.

25

Rothman (WO 8907930 A1 8 Sep 1989) describes a storage-stable protein-containing composition and a method for treating keratinous tissues. The protein-containing composition contains reducing agents such as ammonium thioglycolate. The composition is said to be useful for conditioning horny keratinous tissues of mammals such as human hair and nail, and the hooves and fur of animals, to improve their strength and appearance and to promote hair and nail growth.

35

An enhanced transdermal drug permeation in rats has been reported for theophylline [K. Kushida et al., Chem. Pharm. Bull., 32, 1 (1984) 268-274] and insulin [Y. Sun et al., Ann. New York Academy of Sciences, 1990, 596; Y. Sun et al., Proceed.

Intern. Sym. Control. Rel. Bioactive Mat., 17 (1990) 202; and J. C. Liu et al., in Drug Permeation Enhancement: Theory and Applications, p247-272, (D.S. Hsieh, Ed.) Marcel Dekker, Inc., 1994] by pretreating the skin with aqueous calcium thioglycolate solution. On the other hand, direct addition of calcium thioglycolate into an ointment containing the calcium salt of indomethacin dramatically decreased the absorption of the drug [T. Ogiso et al., J. Pharmcobio-Dyn., 9 (1986) 517-525].

10

Konno et. al. (EP 152281 A2 21 Aug 1985) describes a transdermal formulation of nicardipine hydrochloride containing urea and thioglycol.

15

Brief Description of the Drawings

Fig. 1 shows the treatment target sites of a fungus-infected nail;

20 Fig. 2 is a graph displaying the effect of urea on nail swelling using aqueous urea solutions of various concentrations at pH 4.5;

25 Fig. 3a is a graph showing comparisons of the nail swelling enhancement among several thiol-containing amino acid and analogs after nail clippings were immersed in the formulation at 32°C for 48 hours;

30 Fig. 3b is a graph showing comparisons of the partitioning of itraconazole into nail among several thiol-containing amino acid and analogs after nail clippings were immersed in the formulation at 32°C for 48 hours;

35 Figs. 4a, 5a and 6a are graphs showing the effect of N-acetyl-l-cysteine and urea on nail swelling in different formulations;

Figs. 4b, 5b and 6b are graphs showing the effect of N-acetyl-l-cysteine and urea on itraconazole partitioning into nail in different formulations;

5 Fig. 7 is a graph showing nail swelling and miconazole nitrate partitioning into nail in a miconazole nitrate cream formulation;

10 Fig. 8 is a graph showing the nail swelling - pH profile with nail clippings immersed in a formulation containing urea, propylene carbonate, propylene glycol, N-acetyl-l-cysteine and water, at differing pH values;

15 Fig. 9 is a graph showing the permeation profiles of itraconazole from three formulations with various compositions;

20 Fig. 10 is a graph showing the amount of itraconazole penetrated through the nail plate, as well as the amount retained in the nail plate, for three different formulations;

Fig. 11 is a graph showing the permeation profile of miconazole nitrate through the nail plate for three formulations;

25 Fig. 12 is a graph that shows the amount of miconazole nitrate penetrated through the nail plate, as well as the amount retained in the nail plate, for three formulations; and

Fig. 13 shows three views of a device designed for topical drug delivery to nails.

30

Detailed Description of the Invention

The invention relates to a method for the treatment of fungal diseases in nails, which comprises the topical administration to the nail of (1) a sulphydryl containing amino acid or a derivative thereof, the pharmaceutically acceptable salts or esters thereof, or stereoisomers thereof, (2) urea, (1) and (2)

being administered in an amount sufficient to enhance the permeation of antifungal drugs through nail tissue, either prior to or, preferably, concurrently with the topical administration to the nail of (3) an effective amount of an antifungal drug.

5

The term "nail" means the horny cutaneous plate on the dorsal surface of the distal end of a finger or toe. Fig. 1 is a schematic diagram showing the basic anatomic structure of human nail and its surrounding tissues. The topical antifungal 10 drug treatment for nail fungal disease (onychomycosis) contemplated by this invention is intended to deliver antifungal drug to the nail plate (the stratum corneum unguis) and to the nail bed (the modified area of epidermis beneath the nail, over which the nail plate slides as it grows) through the nail plate. 15 Desirably, antifungal drug is also concurrently administered to the nail matrix (the proximal portion of the nail bed from which growth chiefly proceeds) and nail bed through the skin of the eponychium (commonly called the cuticle) and the hyponychium (the thickened epidermis underneath the free distal end of the 20 nail).

The topical treatment of the invention may be employed in combination with systemic treatment with an antifungal drug such as griseofulvin or other antifungal drug that can be given orally over long periods of time, either concurrently during the 25 entire systemic treatment regimen, or concurrently during a portion (usually the latter phase) of the systemic treatment regimen, or following such systemic treatment.

30 The fungal diseases of the nail that can be treated in accordance with the invention are those that are called "onychomycosis", which is usually an infection by *Epidermophyton floccosum*, several species of *Trichophyton*, or *Candida albicans*.


35 The antifungal drugs that can be used in the invention include miconazole nitrate, ketoconazole, itraconazole, fluconazole, econazole, terconazole, saperconazole, amorolfine,

ciclopirox, oxiconazole, clotrimazole, terbinafine, naftifine, and other antifungal drugs that are available in a topical formulation. The preferred antifungal drugs for use in the process of the invention are itraconazole, ketoconazole and 5 miconazole nitrate. If desired, the topical formulation containing the antifungal drug may include an agent such as hydroxypropyl- β -cyclodextrin that enhances the water-solubility of the antifungal drug, in order to better utilize the aqueous pathway through the nail, as discussed above. The anti-fungal 10 drugs are used in anti-fungally effective amounts. For example, anti-fungally effective amounts are usually from about 0.5% to about 10%, by weight, and preferably from about 1% to about 5%, by weight, of the formulation that is applied to the nail or surrounding dermal tissue.

15

Urea is employed in the invention. It is believed that urea's principal contribution to the efficacy of the formulation used in the invention is to inhibit the nail keratin from returning to its original densely packed cross-linked state 20 (such return to the original densely packed cross-linked state would be caused by oxidation from the oxygen in the atmosphere), so that the nail remains more permeable to the antifungal drug over a longer period of time. (The ability of urea to inhibit the nail keratin from returning to its original densely packed 25 cross-linked state probably stems from urea's ability to disrupt non-covalent interactions in nail keratin.) One beneficial effect of the use of urea is that the sulphydryl-containing amino acid or derivative thereof can be used in a lower concentration, thereby reducing (although probably not eliminating) the potential of the amino acid or derivative thereof for 30 irritation of the skin.

The invention employs a sulphydryl containing amino acid or a derivative thereof, the pharmaceutically acceptable salts or 35 esters thereof, or stereoisomers thereof. Such compounds can be represented by Formula (I):



5 the pharmaceutically acceptable salts or esters thereof,
and stereoisomers thereof,

wherein:

10 R = H, CONHCH₂COOH, NH₂ or COOR² wherein R² is H or C₁₋₄alkyl;


R¹ = H, COCH₃, CONH₂, or CO(CH₂)_mCH(NH₂)(COOH) wherein m is
1 or 2; and

15 n = a number having a value of from 1 to 4.


Illustrative examples of compounds of Formula (I) include
those shown in the following table:

20 TABLE 1


Cysteine (*l*-cysteine, *d*-cysteine, *dl*-cysteine)




N-Acetyl-*l*-cysteine




dl-Homocysteine




1-Cysteine methyl ester (methyl cysteine)




1-Cysteine ethyl ester (ethyl cysteine)



15 N-Carbamoyl cysteine



Glutathione



Cysteamine



The preferred compounds for use in the invention are *N*-acetyl-1-cysteine and cysteine.

40 The urea and the sulfhydryl-containing amino acid or derivative thereof are employed in amounts sufficient to enhance the permeation of antifungal drugs through nail tissue. Thus, the topical composition that is applied to the nail will ordinarily contain from about 1% to about 50%, and preferably from about 5% to about 20%, (by weight) urea, and from about 0.1% to about 40%, and preferably from about 3% to about 20%, (by weight) of the sulfhydryl-containing amino acid or deriva-

tive thereof, the percentages being based upon the total weight of the formulation being applied to the nail. The pH range of the formulation is usually from about pH 2 to pH 10, and preferably from about pH 3 to pH 8.

5

EXPERIMENTAL

a. Effect of nail penetration enhancers on nail swelling and drug partitioning into nail

10

The ability of a drug in a formulation to penetrate nail plate should be reflected by the rate and extent of the nail uptake of the formulation (i.e., nail swelling in the formulation), as well as by the amount of the drug migration into the nail (drug partitioning into nail). In vitro experiments were conducted to examine the effect of drug formulation containing nail penetration enhancer on nail swelling and drug partitioning.

20 The experimental procedure was the following: Clean human nail clippings were equilibrated to a constant weight by placing them in a desiccator over saturated $\text{CaCl}_2 \cdot 6\text{H}_2\text{O}$ solution (29% relative humidity at room temperature) for at least 48 hours before use. Approximately 30 mg of human nail clippings were
25 weighed into a glass vial. The exact initial weight was recorded. Four grams of the test formulation (pre-warmed to 32°C) was added into the vial and maintained at 32°C under stirring in a Heating/Stirring Module (Reacti-Therm III, Pierce). The changes in nail weights were monitored at predetermined intervals over 48 hours. At the end of the swelling experiment, the nail sample was rinsed with a mixture of *N,N*-dimethylformamide and methanol (1:1) to remove surface-bound drug. The nail sample was then digested, and the drug concentration in nail was determined by high pressure liquid chromatography method as described by Badcock and Davies, Assay
30 f itraconazole in nail clippings by reversed phase, high
35

performance liquid chromatography, *Ann. Clin. Biochem.*, 27 (1990) 506-508.

Several terms were used to describe the data. The nail swelling was expressed by the percentage of the initial nail weight (i.e., 100% of the initial nail weight means no swelling, and 200% means a nail swelling doubling the original weight, etc.). An enhancement factor is used to show the increase in nail swelling due to the presence of nail penetration enhancer in comparison to the control, which were calculated according to the formula: enhancement factor = (% weight gain of the test nail sample)/(% weight gain of control nail sample, i.e., no enhancer & urea in the formulation). Similarly, the enhancement factor for the enhanced itraconazole partitioning into nail is defined as: enhancement factor = (drug concentration in the test nail sample)/(drug concentration in the control nail sample). The drug concentration in nail was calculated by dividing the amount of the drug in nail (mg) by the weight of the initial nail clipping (i.e., dry nail weight in gram). This expression of drug nail concentration is used herein unless specified otherwise.

The effect of urea on nail swelling was investigated, using aqueous urea solutions of various concentrations at pH 4.5. The graph shown as Fig. 2 shows that as urea concentration increased from 20% to 40%, nail hydration increased from 30% to 50%. For this reason, it is believed that the use of urea alone will not cause significant enhancement of drug permeation through the nail.

30

TABLE 1, above, shows the names and chemical structures of the thiol-containing amino acids and derivatives thereof that were investigated. To examine the effects of these nail penetration enhancers on nail swelling and drug partitioning, several itraconazole and miconazole nitrate formulations were prepared with an enhancer in each formulation (TABLE 2, below, displays the formulations). In the control experiment, there

was no penetration enhancer ("E") or urea ("U") in the formulation. In the experiments discussed below, the following abbreviations and compounds were used:

5	Ac Cyst	= <i>N</i> -acetyl-l-cysteine
	Cysteine	= l-cysteine
	Homocyst	= dl-homocysteine
	Cysteam	= cysteamine
	MethylCy	= l-cysteine methyl ester
10	EthylCyst	= l-cysteine ethyl ester
	Itra	= itraconazole
	Replen	= replenished every n days
	SA	= salicylic acid (keratolytic agent; pH control)
	PG	= propylene glycol (solvent)
15	PC	= propylene carbonate (solvent)
	EDTA	= ethylenediamine tetraacetic acid (disodium salt - chelating agent)
	KLUCEL	= hydroxypropylcellulose (thickener)
	BHT	= butylated hydroxy toluene (anti-oxidant)
20	Mic.Nit.	= miconazole nitrate
	BHA	= Butylated hydroxyanisole

25 Labrifil M 1944 CS = Unsaturated polyglycolized glycerides obtained by partial alcoholysis of apricot kernel oil, consisting of glycerides and polyethylene glycol esters - an amphiphilic oil, solvent and/or emulsifier.

30 TEFOSE 63 = Ethylene glycol and polyoxyethylene glycol palmitostearate; CTFA adopted name is PEG 6 stearate (and) PEG-32 stearate (and) glycol stearate - a non-ionic self-emulsifying base for oil/water emulsified preparations.

TABLE 2.

ENHANCER	FORMULATIONS							IN WEIGHT %				
	ITRA	ENHANCER	SA	UREA	PC	PG	EDTA	BHT	KLUCEL	H ₂ O	TOTAL	
No E&U	8054-40-5	1	0	0	35	14	0.1	0.05	0	47.85	98	
Ac Cyst	8054-33-3	1	5	10	35	14	0.1	0.05	0	27.85	98	
Cysteine	8054-34-1	1	5	10	35	14	0.1	0.05	0	27.85	98	
Homocyst	8054-34-2	1	5	10	35	14	0.1	0.05	0	27.85	98	
Cyst am	8054-34-3	1	5	10	35	14	0.1	0.05	0	27.85	98	
MethylCY	8054-34-4	1	5	10	35	14	0.1	0.05	0	27.85	98	
EthylCY*	8054-34-5	1	5	10	35	14	0.1	0.05	0	27.85	98	
No Ac&U	8054-40-1	1	0	0	35	10	0.1	0.05	0	51.85	98	
No AC	8054-40-2	1	0	20	35	10	0.1	0.05	0	31.85	98	
No U	8054-40-3	1	5	0	0	35	10	0.1	0.05	0	46.85	98
AC-#23	8054-23	1	5	0	20	35	10	0.1	0.05	0	26.85	98

TABLE 2.

FORMULATIONS		IN WEIGHT %										
ENHANCER		ITRA	ENHANCER	SA	UREA	PC	PG	EDTA	BHT	KLUCEL	H ₂ O	TOTAL
No Ac&U	8054-40-4	1	0	0	0	35	16.5	0.1	0.05	0	45.35	98
%No AC	8054-33-1	1	0	5	10	35	16.5	0.1	0.05	0	30.35	98
No U	8054-33-2	1	5	5	0	35	16.5	0.1	0.05	0	35.35	98
Ac-#26	8054-26	1	5	5	10	35	16.5	0.1	0.05	0	25.35	98
No Ac&U	8054-40-5	1	0	0	0	35	14	0.1	0.05	0	47.85	98
No AC	8054-33-4	1	0	5	10	35	14	0.1	0.05	0	32.85	98
No U	8054-33-5	1	5	5	0	35	14	0.1	0.05	0	37.85	98
Ac-#33-3	8054-33-3	1	5	5	10	35	14	0.1	0.05	0	27.85	98

TABLE 2.

FORMULATIONS		IN WEIGHT %									
ENHANCER		ITRA	ENHANCER	SA	UREA	PC	EDTA	BHT	KLUCEL	H ₂ O	TOTAL
ITRACONAZOLE											
Rep1:3d	2138-41	0.5	10	0	20	35	10	0.1	0.05	0	24.35*
Rep1:d	2138-136	1	5	0	20	35	10	0.1	0.05	2	26.85
R P1:1d	2138-137	1	1	0	20	35	10	0.1	0.05	2	30.85
MICONAZOLE NITRATE											
Rep1:3d	2138-69	2	10	0	20	35	10	0.1	0	0	22.9
Rep1:3d	2138-70	2	5	0	20	35	10	0.1	0	0	27.9
R P1:7d	2138-70	2	5	0	20	35	10	0.1	0	0	27.9
											100

*: Includes 0.1% ascorbic acid.

Fig. 3a shows a comparison of the nail swelling enhancement effect and Fig. 3b shows a comparison of the itraconazole partitioning enhancement effect of the thiol-containing amino acids and derivatives thereof of nail clippings after immersion in the test formulations at 32°C for 48 hours.

The results in the Figure 3a show that all the thiol-containing amino acid and derivatives thereof investigated increased nail swelling in the itraconazole formulations, with the enhancement factors ranging from 1.82 to 4.57. The highest nail swelling enhancement was found with l-cysteine, followed by N-acetyl-l-cysteine and cysteamine. As shown in Figure 3b, the same rank order was observed among the penetration enhancers for their ability in enhancing itraconazole partitioning into nail. The drastic increase in itraconazole migration into the nail (approximately 100-fold) indicates that incorporation of the penetration enhancer into a topical itraconazole formulation will definitely facilitate the antifungal drug reaching its target sites in the nail plate and the nail bed.

20

The graphs displayed in Figs. 4a-6a and 4b-6b show the effect of N-acetyl-l-cysteine as penetration enhancer, and urea as adjuvant synergist on the nail swelling and itraconazole partitioning. The compositions of the formulations are tabulated in Table 3, below. All three itraconazole formulations contain 1% itraconazole, 5% N-acetyl-l-cysteine, and different concentration of urea and other components. The pH of these formulations was adjusted to 3.0. As can be seen from these figures, by adjusting the composition of a formulation, one can obtain the desired performance from the formulation, as reflected by nail swelling and itraconazole partitioning. The benefit of incorporating urea into the formulations is demonstrated by a clear trend shown in 4a-6a and 4b-6b. As can be seen, the increase of itraconazole partitioning into nail owing to the presence of urea is higher than the increase of nail swelling in all three formulations.

TABLE 3.

ENHAN-CER	FORMULATIONS	SWELLING (%wt x 100)			ITRA PARTITIONING (mg/g)		
		Avg	STD	Enh. F	Avg	STD	Enh. F
No E&U	8054-4-0-5	1.35	0.01	1	0.047	0.011	1
Ac Cyst	8054-3-3-3	2.11	0.04	3.18	4.365	0.520	93.6
Cysteine	8054-3-4-1	2.59	0.03	4.57	4.897	0.149	105.0
Homocyst	8054-3-4-2	1.71	0.05	2.04	1.097	0.230	23.5
Cysteam	8054-3-4-3	2.06	0.01	3.03	2.632	0.181	56.5
MethylCys	8054-3-4-4	1.73	0.04	2.09	1.430	0.073	30.7
EthylCys	8054-3-4-5	1.64	0.05	1.82	1.221	0.213	26.2

TABLE 3.

No	Ac&U	8054-4-0-5	1.43	0.03	1	0.061	0.031	1
No	AC	8054-4-0-2	1.43	0.06	1.01	0.068	0.031	1.1
No	U	8054-4-0-3	3.32	0.23	5.45	0.990	0.405	16.2
Ac-#23		8054-23	3.61	0.39	6.12	0.853	0.112	13.9
<hr/>								
No	Ac&U	8054-4-0-4	1.36	0.06	1	0.059	0.012	1
No	AC	8054-33-1	1.42	0.05	1.18	0.670	0.153	11.3
No	U	8054-33-2	1.80	0.06	2.26	2.132	0.095	36.0
Ac-#26		8054-26	2.06	0.06	2.97	3.293	0.303	55.5

TABLE 3.

No	Ac&U	8054-40 -5	1.35	0.01	1	0.047	0.011	1
No	Ac	8054-33 -4	1.52	0.02	1.5	0.940	0.167	20.2
No	U	8054-33 -5	1.90	0.06	2.57	2.281	0.339	48.9
Ac-#33-	3	8054-33 -3	2.11	0.04	3.18	4.365	0.520	93.6
PERMEATION								
ITRACONAZOLE		(ug/cm ²)		(ug/cm ²)		(ug/cm ³)		
NAIL PERMEATION		Avg	STD	Avg	STD	Avg	STD	
Repl:3d	2138-41	22.28	8.66	50.31	20.35	1096.5	516.1	
Repl:1d	2138-13 6	49.05	31.79	41.06	9.83	691.6	230.1	

TABLE 3.

Rep1:1d	2138-13 7	0.00	0.00	12.53	6.22	221.9	138.4
*: Calculation based on the initial volume of the untreated nail.							
MICONAZOLE NITRATE	PERMEATION	MICONAZOLE NITRATE IN NAIL					
NAIL PERMEATION	(ug/cm ²))		(ug/cm ²))			(ug/cm ³) *)	
	AVG	STD	AVG	STD	AVG	STD	
Rep1:3d	2138-69 4484	952	11215	967	221654	50389	
Rep1:3d	2138-70 1889	278	4924	2268	99384	59786	
Rep1:7d	2138-70 1431	147	6001	1371	99998	11316	
*: Calculation based on the initial volume of the untreated nail.							

*: $\mu\text{g}/\text{cm}^3 = \mu\text{g}/\text{cm}^2/\text{nail thickness } (\text{cm})$

A nail swelling and drug partitioning experiment was also conducted for miconazole nitrate using procedures analogous to those described above. The graphed results shown in Fig. 7 show that, similar to itraconazole data, significant nail swelling coincided with substantial miconazole partitioning into the nail, using the following formulation:

10 1% Miconazole nitrate, 0.005% BHA, 1.5% heavy mineral oil, 1.5% peglicol 5 oleate (LABRAFIL M 1944 CS),, 10% pegoxol 7 stearate (TEFOSE 63), 0.05% EDTA, 20% urea, 10% N-acetyl-l-cysteine, and 55.9% water, with pH adjusted to 9.0 with NaOH, as required.

15 It should be noted that, unlike the itraconazole formulations discussed above, which were tested at pH 3, the pH value of the miconazole nitrate formulation was set at pH 9. The significant nail swelling and coinciding high miconazole-nail partitioning indicate that N-acetyl-l-cysteine has a wide working pH range. This was confirmed by the swelling-pH profile 20 shown in Fig. 8, using the following formulation:

25 20% urea, 35% propylene carbonate, 10% propylene glycol, 10% N-acetyl-l-cysteine and 25% water, with pH adjusted with HCl or NaOH, as required, to pH 3.2, 4.0, 5.0, 6.0 and 7.0. The experimental temperature was 32°C.

b. Effect of nail penetration enhancers on drug permeation through nail and the drug retention and distribution in the nail plate

30

To test the enhancement effect of N-acetyl-l-cysteine containing itraconazole formulation, itraconazole permeation experiments were conducted using human cadaver nails. Briefly, a nail plate was mounted on a nail diffusion cell (exposed nail area = 0.1202 cm²) in which the nail separated a donor chamber from a receptor chamber. The donor chamber was then charged with an itraconazole formulation of 100 - 200 mg. To simulate

the clinical situation, the drug formulation in the donor chamber was removed, and replenished with fresh drug formulation according to a pre-determined time schedule. The solution in the receptor chamber was 20% aqueous hydroxypropyl- β -cyclo-dextrin (5 ml, pH 4) to ensure sink conditions. ["Sink condition" is defined as a condition wherein the concentration of the permeant (in this case, itraconazole) in the receptor solution is lower than 10% of its solubility in the receptor solution - the idea is to drive the equilibrium such that the permeation of the permeant into the receptor solution is favored.] The experiments were run under occlusive conditions (i.e., the donor compartment was covered with a PVC film to minimize evaporation and to exclude the atmospheric oxygen) and at 32°C. With a predetermined sampling schedule, an aliquot of receptor solution was removed for itraconazole HPLC assay, and was replaced with an equal volume of fresh receptor medium. A typical nail permeation experiment ran for about 4 weeks. At the end of the permeation experiment, the itraconazole content in the nail plate was also determined by HPLC after the extraction procedure cited above (Badcock and Davies). Similar experiments were also conducted for miconazole nitrate nail permeation.

As shown in Fig. 9, the itraconazole nail permeation profiles of formulations #41 & #136 show that itraconazole started to penetrate through the nail plates to reach the receptor in approximately 12 days. The formulation #136 has an itraconazole nail permeation rate double that of formulation #41, probably due to its itraconazole content (1.0% itraconazole in #136 and 0.5% itraconazole in #41), despite the fact that formulation #41 has twice as much acetyl cysteine (10% acetyl cysteine) as formulation #136 (5% acetyl cysteine). Formulation #137 has an almost identical composition to Formulation #136, except it has a lower acetyl cysteine content (only 1.0% acetyl cysteine in #137, as opposed to 5.0% in #136). Fig. 9 shows that formulation #137 failed to deliver itraconazole across the nail plate. Apparently, the acetyl cysteine

concentration in formulation #137 was too low to exert acetyl cysteine's penetration enhancing effect. Fig. 10 shows the total amount of itraconazole penetrated into the nail, including the itraconazole permeated through the nail plate, and the drug
5 retained by the nail. The substantial amount of the drug retained in the nail reflects the highly keratinophilic nature of itraconazole. It is interesting to see that the total amount of itraconazole penetrated into the nail from formulation #137 is about 1/5 of that from formulation #136 (the same ratio as
10 the acetyl cysteine contents of the two formulations).

It should be noted that in the in vitro experiments, the amount of itraconazole penetrated into and through the nail plate greatly exceeded the therapeutically required dose. For
15 example (TABLE 3), formulation #2138-41 achieved an itraconazole nail concentration of 1096 µg/ml, and formulation #2138-136 achieved a concentration of 692 µg/ml. Itraconazole is a highly potent antifungal drug with a very broad spectrum of activity. The minimal inhibitory concentration (MIC) of itraconazole
20 against both dermatophites and yeasts is as low as 100 ng/ml.

Fig. 11 shows the permeation profile of miconazole nitrate. As can been seen, starting at day 5 (lag time = 5 days), miconazole nitrate penetrated through the nail plates with a
25 constant rate. With the same formulation, i.e., formulation #70, the frequency of replenishing the formulation (every 3 days or every 7 days) did not lead to much difference in miconazole nitrate permeation through the nail, nor in the amount of the drug retained in the nail (Figure 12). On the other hand, when
30 the concentration of N-acetyl-l-cysteine was increased from 5% (Formulation #70) to 10% (Formulation #69), both the miconazole nitrate permeation rate and drug retention in the nail doubled. This result indicates that the nail permeation performance of a drug formulation can be easily adjusted by choosing an appropriate
35 penetration enhancer level. Fig. 12 shows the amount of miconazole nitrate penetrated through the nail plate, as well as the amount retained in the nail plate. The substantial amount

of the drug retained in the nail reflects the keratinophilic nature of miconazole.

5 c. Stability of itraconazole formulation containing N-acetyl-L-cysteine as nail penetration enhancer and urea as penetration synergist

10 An accelerated stability test on formulation #41 shows that at 99.46% of initial itraconazole in the formulation remained intact after 13 weeks in at 50°C, indicating that itraconazole in the formulation is stable enough to meet the 2-year shelf life requirement at ambient temperature.

15 d. Primary Dermal Irritation Test

20 Primary dermal irritation tests conducted on guinea pigs using two 1% itraconazole formulations (formulations #97 & #98) containing 1% and 5% acetyl cysteine, respectively. The results show that these formulations meet the requirement as topical therapeutic formulation.

25 e. A specially designed nail medication delivery device and a two-stage treatment regimen for topical antifungal therapy

30 Because sulfhydryl compounds are highly oxidizable by the oxygen in the air, the stability of a sulfhydryl nail penetration enhancer during storage presents a problem. For this reason, an antifungal formulation containing the sulfhydryl penetration enhancer are preferably applied to the nail in a specially designed nail medication delivery device in order to maintain the potency of the nail penetration enhancer. The device is designed to:

- 35 (a) inhibit the sulfhydryl penetration enhancer from oxidation by oxygen in the air;

- (b) provide an occlusive environment for nail swelling to take place;
- (c) prevent the sensitive eponychium skin from direct contact with the sulfhydryl penetration enhancer;
- 5 (d) firmly adhere to the nail and surrounding skin with desired contour and pliability; and
- (e) be convenient for patients to use.

Urea tends to undergo a biuret reaction during storage, which could cause a pH shift in the formulation. Since the solubility of some antifungal drugs such as itraconazole decreases as the formulation pH increases, the pH shift would significantly reduce the dissolved form of itraconazole available for penetration, thereby reducing its therapeutic efficacy. The stability problem of the sulfhydryl nail penetration enhancer during storage and application, and the pH shifting problem due to urea, may be resolved by using a nail medication delivery device designed as described below. The nail medication delivery device comprises a bandage adapted for the topical administration of medication to the nail, said bandage comprising a T-shaped adhesive backing, and a flexible pad having an impervious backing and a nail-shaped cavity, wherein said nail-shaped cavity contains absorptive means having absorbed therein urea and sulfhydryl penetration enhancer, both of said compounds being in a water-free condition. That is, the absorptive means is sufficiently free of water that the urea and sulfhydryl penetration enhancer remain stable under ordinary storage conditions (at 25°C) for a reasonable shelf life period of, e.g., at least six to twelve months.

30

This nail medication delivery device includes dehydrated sulfhydryl penetration enhancer and urea in its structure, separate from the antifungal drug formulation, hence greatly reducing the instability problem. Fig. 13 shows the nail medication delivery device 10. The device includes a pliable polyethylene closed-cell foam pad 14 (the pad 14 is preferably adhesive-coated on the surface that will be in contact with the

finger or toe whose nail is being treated) that includes a nail shaped cavity or well defined by walls 12a-d and an impervious backing 16 (which can be a portion of the adhesive backing 18). The well contains a nonwoven pad or a lyophilized porous layer 22 that contains a predetermined amount of sulfhydryl nail penetration enhancer and urea. (In lieu of the pad or layer 22, other conventional absorption means for storing the urea and sulfhydryl nail penetration enhancer may be used.) This pad or layer 22 serves as a drug reservoir. The impervious backing 16 helps to keep moisture in and oxygen out. The adhesive backing 18 is arranged to form a T-shaped bandage 10, which secures the drug formulation-containing nail medication delivery device 10 on a finger tip or toe 20. The nail medication delivery device 10 is preferably stored in a metallic laminate blister package (not shown), which may be filled with an inert gas such as N₂ or argon, to help ensure the shelf-life of the urea and sulfhydryl nail penetration enhancer. During a clinical application, a stable itraconazole formulation containing no sulfhydryl penetration enhancer and urea, and packaged in a conventional tube, is charged into the drug reservoir 22 of the device by application to the surface of the nonwoven pad or a lyophilized porous layer (or other absorption means). *N*-acetyl-l-cysteine [or other compound of Formula (I)] and urea immediately dissolve in the drug formulation, and exert their penetration enhancing effect to the nail 20, when applied to the nail during treatment. Another advantage of the enhancer-containing nail device is its universal usefulness for any antifungal drug formulation.

Because the combination of sulfhydryl nail penetration enhancer and urea has a prolonged enhancement effect on the nail permeability for the antifungal drug, a two-stage antifungal treatment regimen may be employed. The first stage consists of an initial treatment period (e.g., 1-3 weeks) with a topical antifungal formulation and a nail drug delivery device, which contains both sulfhydryl penetration enhancer and urea. As discussed above, the nail medication delivery device is designed in such a way that it provides occlusive conditions, that is,

oxygen exclusion to enhance the stability of the nail penetration enhancer, and moisture retention to maximize the water content of the nail, thereby to promote high drug penetration. By the end of the first stage treatment, nail permeability to 5 the antifungal drug has been increased significantly, and a sufficient amount of antifungal drug has reached the targeted sites (i.e., nail plate, nail bed and nail matrix) to exert antifungal action. The strong binding between certain antifungal drugs (e.g., itraconazole and miconazole) and nail keratin 10 will likely result in a drug concentration in nail significantly above its therapeutic level for a long time. The second stage of the treatment is a maintenance therapy involving periodic applications of antifungal formulation without the penetration enhancer and urea. (This is possible because the urea acts to 15 prevent the keratin from returning to its original densely packed cross-linked state, thereby maintaining the permeability of the nail to the antifungal drug formulation.) The simplified procedure of the maintenance stage is user-friendly, and will help encourage long-term compliance by patients.

20

The following are representative formulations of antifungal drug, penetration enhancer and urea that are suitable for use in the invention:

FORMULATION A w/w%

25	Miconazole nitrate	2.0%
	Propylene carbonate	35.0%
	Propylene glycol	10.0%
	EDTA	0.1%
	Urea	20.0%
30	l-Cysteine	10.0%
	Purified water	22.9%
	Adjust pH to 8.00 with aq. 50% NaOH	

35 Note: Formulations containing miconazole nitrate can have pH values of from about 3 to about 9.

FORMULATION B (pH 8) w/w%

40	Miconazole nitrate	1.0%
	Propylene carbonate	20.0%
	Propylene glycol	10.0%
	EDTA	0.1%
	Urea	20.0%

5 l-Cysteine 10.0%
 Isopropyl alcohol 10.0%
 Adjust pH to 8.00 with aq. 50% NaOH
 QS with distilled water to 100% (approx. 28%)

5

FORMULATION C (pH 9) (w/w%)

10 Miconazole nitrate 1.0%
 Propylene carbonate 20.0%
 Propylene glycol 10.0%
 EDTA 0.1%
 Urea 20.0%
 l-Cysteine 10.0%
 Isopropyl alcohol 10.0%
 Adjust pH to 9.00 with aq. 50% NaOH
 QS with distilled water to 100% (approx. 28%)

20 FORMULATION D (pH 8) (w/w%)

25 Miconazole nitrate 1.0%
 Propylene carbonate 20.0%
 Propylene glycol 10.0%
 EDTA 0.1%
 Urea 20.0%
 N-acetyl-l-cysteine 10.0%
 Isopropyl alcohol 10.0%
 Adjust pH to 8.00 with 50% aq. NaOH
 QS with distilled water to 100% (approx. 28%)

FORMULATION E (pH 9) (w/w%)

35 Miconazole nitrate 1.0%
 Propylene carbonate 20.0%
 Propylene glycol 10.0%
 EDTA 0.1%
 Urea 20.0%
 N-acetyl-l-cysteine 10.0%
 Isopropyl alcohol 10.0%
 Adjust pH to 9.00 with 50% aq. NaOH
 QS with distilled water to 100% (approx. 28%)

45 FORMULATION F (CREAM) w/w%

50 BHA, NF 0.01%
 Miconazole nitrate, USP 2.00%
 Mineral oil, USP (heavy) 3.00%
 Peglicol 5 Oleate (LABRAFIL M 1944 CS) 3.00%
 PEGOXOL 7 stearate (TEFOSE 63) 20.00%
 EDTA 0.10%
 Urea 20.00%
 N-acetyl-l-cysteine 10.00%
 Adjust to pH 8.00 with 50% aq. NaOH

QS with Purified water (USP) to 100% (approx. 40%)

The following is a formulation of antifungal drug suitable for use after the nail has been treated with penetration enhancer and urea, as described above.

FORMULATION G (CREAM)

w/w%

10	Benzoic acid, USP	0.2000%
	BHA, NF	0.0052%
	Miconazole nitrate, USP	2.0000%
	Mineral oil, USP (heavy)	3.0000%
	Peglicol 5 Oleate (LABRAFIL M 1944 CS)	3.0000%
15	Pegoxol 7 stearate (TEFOSE 63)	20.0000%
	Purified water, USP	71.7948%
	pH 3-4	

The following are preferred formulations containing itraconazole:

FORMULATION H (pH 3)

w/w%

20	Itraconazole	1.0%
	Propylene carbonate	35.0%
25	Propylene glycol	16.5%
	EDTA	0.1%
	Urea	10.0%
	N-acetyl-l-cysteine	5.0%
	Salicylic acid	5.0%
30	BHT	0.05%
	Adjust pH to 3.0 with 1 N NaOH	
	QS with distilled water to 100%	(approx. 25%)

Note: Formulations containing itraconazole preferably have a relatively low pH, such as from about pH 2 to pH 4, in order to enhance the solubility of itraconazole in the formulation.

FORMULATION I (pH 3)

w/w%

40	Itraconazole	1.0%
	Propylene carbonate	35.0%
	Propylene glycol	14.0%
	EDTA	0.1%
45	Urea	10.0%
	N-acetyl-l-cysteine	5.0%
	Salicylic acid	5.0%
	BHT	0.05%
50	Adjust pH to 3.0 with 1 N NaOH	
	QS with distilled water to 100%	(approx. 27.5%)

FORMULATION J (pH 3)w/w%

5	Itraconazole	1.0%
	propylene carbonate	35.0%
	Propylene glycol	10.0%
	Urea	10.0%
	Acetylcysteine	5.0%
	Disodium EDTA	0.1%
10	BHT	0.1%
	Klucel	2.0%
	pH adjusted to 3 with 0.1N HCl	
	Water Q.S.	100.00%

FORMULATION K (pH 3)w/w%

15	Itraconazole	1.0%
	Propylene carbonate	35.0%
	Propylene glycol	10.0%
20	Urea	20.0%
	Acetylcysteine	5.0%
	Disodium EDTA	0.1%
	BHT	0.1%
	Klucel	2.0%
25	pH adjusted to 3 with 0.1N HCl	
	Water Q.S.	100.00%

FORMULATION LWeight

30	Itraconazole	50 mg
	Propylene carbonate	350 mg
	Propylene glycol	100 mg
	Urea	200 mg
35	N-Acetyl-l-cysteine	50 mg
	Hydroxypropyl cellulose	20 mg
	EDTA (Na salt)	1 mg
	BHT	0.5 mg
40	Conc. HCl q.s. to pH 3	
	Purified water q.s. ad	1000 mg

Formulations containing from about 10 to 50% (by weight) propylene carbonate (4-methyl-1,3-dioxolan-2-one) and about 5 to 45 30% propylene glycol are desirable because itraconazole and other anti-fungal compounds that have low solubility in water are soluble in such formulations. These compounds also help to enhance penetration of the anti-fungal drug into the nail.

Treatment Trials with Volunteers:

1: A 57 year old female had onychomycosis of the left thumb nail for approximately 20 years. The involved nail plate had a characteristic groovy uneven surface. A topical formulation containing 1% Itraconazole, 5% acetyl cysteine, 10% urea and other pharmaceutical excipients (similar to Formulation H) was applied to the nail, under occluded conditions, daily for seven days. At the same time a similar formulation, but without acetyl cysteine, was applied to the skin surrounding the nail. A six-month follow-up showed the nail to be clinically cured.


5 The newly grown nail had a healthy normal appearance.

10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995
1000
1005
1010
1015
1020
1025
1030
1035
1040
1045
1050
1055
1060
1065
1070
1075
1080
1085
1090
1095
1100
1105
1110
1115
1120
1125
1130
1135
1140
1145
1150
1155
1160
1165
1170
1175
1180
1185
1190
1195
1200
1205
1210
1215
1220
1225
1230
1235
1240
1245
1250
1255
1260
1265
1270
1275
1280
1285
1290
1295
1300
1305
1310
1315
1320
1325
1330
1335
1340
1345
1350
1355
1360
1365
1370
1375
1380
1385
1390
1395
1400
1405
1410
1415
1420
1425
1430
1435
1440
1445
1450
1455
1460
1465
1470
1475
1480
1485
1490
1495
1500
1505
1510
1515
1520
1525
1530
1535
1540
1545
1550
1555
1560
1565
1570
1575
1580
1585
1590
1595
1600
1605
1610
1615
1620
1625
1630
1635
1640
1645
1650
1655
1660
1665
1670
1675
1680
1685
1690
1695
1700
1705
1710
1715
1720
1725
1730
1735
1740
1745
1750
1755
1760
1765
1770
1775
1780
1785
1790
1795
1800
1805
1810
1815
1820
1825
1830
1835
1840
1845
1850
1855
1860
1865
1870
1875
1880
1885
1890
1895
1900
1905
1910
1915
1920
1925
1930
1935
1940
1945
1950
1955
1960
1965
1970
1975
1980
1985
1990
1995
2000
2005
2010
2015
2020
2025
2030
2035
2040
2045
2050
2055
2060
2065
2070
2075
2080
2085
2090
2095
2100
2105
2110
2115
2120
2125
2130
2135
2140
2145
2150
2155
2160
2165
2170
2175
2180
2185
2190
2195
2200
2205
2210
2215
2220
2225
2230
2235
2240
2245
2250
2255
2260
2265
2270
2275
2280
2285
2290
2295
2300
2305
2310
2315
2320
2325
2330
2335
2340
2345
2350
2355
2360
2365
2370
2375
2380
2385
2390
2395
2400
2405
2410
2415
2420
2425
2430
2435
2440
2445
2450
2455
2460
2465
2470
2475
2480
2485
2490
2495
2500
2505
2510
2515
2520
2525
2530
2535
2540
2545
2550
2555
2560
2565
2570
2575
2580
2585
2590
2595
2600
2605
2610
2615
2620
2625
2630
2635
2640
2645
2650
2655
2660
2665
2670
2675
2680
2685
2690
2695
2700
2705
2710
2715
2720
2725
2730
2735
2740
2745
2750
2755
2760
2765
2770
2775
2780
2785
2790
2795
2800
2805
2810
2815
2820
2825
2830
2835
2840
2845
2850
2855
2860
2865
2870
2875
2880
2885
2890
2895
2900
2905
2910
2915
2920
2925
2930
2935
2940
2945
2950
2955
2960
2965
2970
2975
2980
2985
2990
2995
3000
3005
3010
3015
3020
3025
3030
3035
3040
3045
3050
3055
3060
3065
3070
3075
3080
3085
3090
3095
3100
3105
3110
3115
3120
3125
3130
3135
3140
3145
3150
3155
3160
3165
3170
3175
3180
3185
3190
3195
3200
3205
3210
3215
3220
3225
3230
3235
3240
3245
3250
3255
3260
3265
3270
3275
3280
3285
3290
3295
3300
3305
3310
3315
3320
3325
3330
3335
3340
3345
3350
3355
3360
3365
3370
3375
3380
3385
3390
3395
3400
3405
3410
3415
3420
3425
3430
3435
3440
3445
3450
3455
3460
3465
3470
3475
3480
3485
3490
3495
3500
3505
3510
3515
3520
3525
3530
3535
3540
3545
3550
3555
3560
3565
3570
3575
3580
3585
3590
3595
3600
3605
3610
3615
3620
3625
3630
3635
3640
3645
3650
3655
3660
3665
3670
3675
3680
3685
3690
3695
3700
3705
3710
3715
3720
3725
3730
3735
3740
3745
3750
3755
3760
3765
3770
3775
3780
3785
3790
3795
3800
3805
3810
3815
3820
3825
3830
3835
3840
3845
3850
3855
3860
3865
3870
3875
3880
3885
3890
3895
3900
3905
3910
3915
3920
3925
3930
3935
3940
3945
3950
3955
3960
3965
3970
3975
3980
3985
3990
3995
4000
4005
4010
4015
4020
4025
4030
4035
4040
4045
4050
4055
4060
4065
4070
4075
4080
4085
4090
4095
4100
4105
4110
4115
4120
4125
4130
4135
4140
4145
4150
4155
4160
4165
4170
4175
4180
4185
4190
4195
4200
4205
4210
4215
4220
4225
4230
4235
4240
4245
4250
4255
4260
4265
4270
4275
4280
4285
4290
4295
4300
4305
4310
4315
4320
4325
4330
4335
4340
4345
4350
4355
4360
4365
4370
4375
4380
4385
4390
4395
4400
4405
4410
4415
4420
4425
4430
4435
4440
4445
4450
4455
4460
4465
4470
4475
4480
4485
4490
4495
4500
4505
4510
4515
4520
4525
4530
4535
4540
4545
4550
4555
4560
4565
4570
4575
4580
4585
4590
4595
4600
4605
4610
4615
4620
4625
4630
4635
4640
4645
4650
4655
4660
4665
4670
4675
4680
4685
4690
4695
4700
4705
4710
4715
4720
4725
4730
4735
4740
4745
4750
4755
4760
4765
4770
4775
4780
4785
4790
4795
4800
4805
4810
4815
4820
4825
4830
4835
4840
4845
4850
4855
4860
4865
4870
4875
4880
4885
4890
4895
4900
4905
4910
4915
4920
4925
4930
4935
4940
4945
4950
4955
4960
4965
4970
4975
4980
4985
4990
4995
5000
5005
5010
5015
5020
5025
5030
5035
5040
5045
5050
5055
5060
5065
5070
5075
5080
5085
5090
5095
5100
5105
5110
5115
5120
5125
5130
5135
5140
5145
5150
5155
5160
5165
5170
5175
5180
5185
5190
5195
5200
5205
5210
5215
5220
5225
5230
5235
5240
5245
5250
5255
5260
5265
5270
5275
5280
5285
5290
5295
5300
5305
5310
5315
5320
5325
5330
5335
5340
5345
5350
5355
5360
5365
5370
5375
5380
5385
5390
5395
5400
5405
5410
5415
5420
5425
5430
5435
5440
5445
5450
5455
5460
5465
5470
5475
5480
5485
5490
5495
5500
5505
5510
5515
5520
5525
5530
5535
5540
5545
5550
5555
5560
5565
5570
5575
5580
5585
5590
5595
5600
5605
5610
5615
5620
5625
5630
5635
5640
5645
5650
5655
5660
5665
5670
5675
5680
5685
5690
5695
5700
5705
5710
5715
5720
5725
5730
5735
5740
5745
5750
5755
5760
5765
5770
5775
5780
5785
5790
5795
5800
5805
5810
5815
5820
5825
5830
5835
5840
5845
5850
5855
5860
5865
5870
5875
5880
5885
5890
5895
5900
5905
5910
5915
5920
5925
5930
5935
5940
5945
5950
5955
5960
5965
5970
5975
5980
5985
5990
5995
6000
6005
6010
6015
6020
6025
6030
6035
6040
6045
6050
6055
6060
6065
6070
6075
6080
6085
6090
6095
6100
6105
6110
6115
6120
6125
6130
6135
6140
6145
6150
6155
6160
6165
6170
6175
6180
6185
6190
6195
6200
6205
6210
6215
6220
6225
6230
6235
6240
6245
6250
6255
6260
6265
6270
6275
6280
6285
6290
6295
6300
6305
6310
6315
6320
6325
6330
6335
6340
6345
6350
6355
6360
6365
6370
6375
6380
6385
6390
6395
6400
6405
6410
6415
6420
6425
6430
6435
6440
6445
6450
6455
6460
6465
6470
6475
6480
6485
6490
6495
6500
6505
6510
6515
6520
6525
6530
6535
6540
6545
6550
6555
6560
6565
6570
6575
6580
6585
6590
6595
6600
6605
6610
6615
6620
6625
6630
6635
6640
6645
6650
6655
6660
6665
6670
6675
6680
6685
6690
6695
6700
6705
6710
6715
6720
6725
6730
6735
6740
6745
6750
6755
6760
6765
6770
6775
6780
6785
6790
6795
6800
6805
6810
6815
6820
6825
6830
6835
6840
6845
6850
6855
6860
6865
6870
6875
6880
6885
6890
6895
6900
6905
6910
6915
6920
6925
6930
6935
6940
6945
6950
6955
6960
6965
6970
6975
6980
6985
6990
6995
7000
7005
7010
7015
7020
7025
7030
7035
7040
7045
7050
7055
7060
7065
7070
7075
7080
7085
7090
7095
7100
7105
7110
7115
7120
7125
7130
7135
7140
7145
7150
7155
7160
7165
7170
7175
7180
7185
7190
7195
7200
7205
7210
7215
7220
7225
7230
7235
7240
7245
7250
7255
7260
7265
7270
7275
7280
7285
7290
7295
7300
7305
7310
7315
7320
7325
7330
7335
7340
7345
7350
7355
7360
7365
7370
7375
7380
7385
7390
7395
7400
7405
7410
7415
7420
7425
7430
7435
7440
7445
7450
7455
7460
7465
7470
7475
7480
7485
7490
7495
7500
7505
7510
7515
7520
7525
7530
7535
7540
7545
7550
7555
7560
7565
7570
7575
7580
7585
7590
7595
7600
7605
7610
7615
7620
7625
7630
7635
7640
7645
7650
7655
7660
7665
7670
7675
7680
7685
7690
7695
7700
7705
7710
7715
7720
7725
7730
7735
7740
7745
7750
7755
7760
7765
7770
7775
7780
7785
7790
7795
7800
7805
7810
7815
7820
7825
7830
7835
7840
7845
7850
7855
7860
7865
7870
7875
7880
7885
7890
7895
7900
7905
7910
7915
7920
7925
7930
7935
7940
7945
7950
7955
7960
7965
7970
7975
7980
7985
7990
7995
8000
8005
8010
8015
8020
8025
8030
8035
8040
8045
8050
8055
8060
8065
8070
8075
8080
8085
8090
8095
8100
8105
8110
8115
8120
8125
8130
8135
8140
8145
8150
8155
8160
8165
8170
8175
8180
8185
8190
8195
8200
8205
8210
8215
8220
8225
8230
8235
8240
8245
8250
8255
8260
8265
8270
8275
8280
8285
8290
8295
8300
8305
8310
8315
8320
8325
8330
8335
8340
8345
8350
8355
8360
8365
8370
8375
8380
8385
8390
8395
8400
8405
8410
8415
8420
8425
8430
8435
8440
8445
8450
8455
8460
8465
8470
8475
8480
8485
8490
8495
8500
8505
8510
8515
8520
8525
8530
8535
8540
8545
8550
8555
8560
8565
8570
8575
8580
8585
8590
8595
8600
8605
8610
8615
8620
8625
8630
8635
8640
8645
8650
8655
8660
8665
8670
8675
8680
8685
8690
8695
8700
8705
8710
8715
8720
8725
8730
8735
8740
8745
8750
8755
8760
8765
8770
8775
8780
8785
8790
8795
8800
8805
8810
8815
8820
8825
8830
8835
8840
8845
8850
8855
8860
8865
8870
8875
8880
8885
8890
8895
8900
8905
8910
8915
8920
8925
8930
8935
8940
8945
8950
8955
8960
8965
8970
8975
8980
8985
8990
8995
9000
9005
9010
9015
9020
9025
9030
9035
9040
9045
9050
9055
9060
9065
9070
9075
9080
9085
9090
9095
9100
9105
9110
9115
9120
9125
9130
9135
9140
9145
9150
9155
9160
9165
9170
9175
9180
9185
9190
9195
9200
9205
9210
9215
9220
9225
9230
9235
9240
9245
9250
9255
9260
9265
9270
9275
9280
9285
9290
9295
9300
9305
9310
9315
9320
9325
9330
9335
9340
9345
9350
9355
9360
9365
9370
9375
9380
9385
9390
9395
9400
9405
9410
9415
9420
9425
9430
9435
9440
9

WHAT IS CLAIMED IS:

1. A method for the treatment of fungal diseases in
nails, which comprises the topical administration to the
5 affected nail, or to the affected nail and surrounding skin, of:

(1) a compound represented by Formula (I):



the pharmaceutically acceptable salts or esters thereof,
and stereoisomers thereof,

15 wherein:

R = H, CONHCH₂COOH, NH₂ or COOR² wherein R² is H or C₁₋₄alkyl;

20 R¹ = H, COCH₃, CONH₂, or CO(CH₂)_mCH(NH₂)(COOH) wherein m is
1 or 2; and

n = a number having a value of from 1 to 4; and

25 (2) urea; and

(3) an effective amount of an antifungal drug, (1) and (2)
being administered in an amount sufficient to enhance the perme-
ation of said antifungal drug through nail tissue, and (1) and
30 (2) being administered either prior to or concurrently with the
topical administration to the nail of said antifungal drug.

2. The method of Claim 1 wherein the compound represented
by Formula (I) is selected from the group consisting of l-
35 cysteine, cysteine, d-cysteine, dl-cysteine, N-acetyl-l-
cysteine, dl-homocysteine, l-cysteine methyl ester, l-cysteine
ethyl ester, N-carbamoyl cysteine, glutathione and cysteamine.

3. The method of Claim 2 wherein the compound represented by Formula (I) is N-acetyl-L-cysteine or cysteine.

4. The method of Claim 1 wherein the antifungal drug is
5 selected from the group consisting of miconazole, ketoconazole, itraconazole, fluconazole, econazole, ciclopirox, oxiconazole, clotrimazole, terbinafine, naftifine, pharmaceutically acceptable salts thereof and stereoisomers thereof.

10 5. The method of Claim 2 wherein the antifungal drug is selected from the group consisting of miconazole, ketoconazole, itraconazole, fluconazole, econazole, ciclopirox, oxiconazole, clotrimazole, terbinafine, naftifine, pharmaceutically acceptable salts thereof and stereoisomers thereof.

15 6. The method of Claim 3 wherein the antifungal drug is selected from the group consisting of miconazole, ketoconazole, itraconazole, fluconazole, econazole, ciclopirox, oxiconazole, clotrimazole, terbinafine, naftifine, pharmaceutically acceptable salts thereof and stereoisomers thereof.

20 7. The method of Claim 4 wherein the antifungal drug is selected from the group consisting of miconazole, ketoconazole, itraconazole, pharmaceutically acceptable salts thereof and
25 stereoisomers thereof.

30 8. The method of Claim 5 wherein the antifungal drug is selected from the group consisting of miconazole, ketoconazole, itraconazole, pharmaceutically acceptable salts thereof and
stereoisomers thereof.

35 9. The method of Claim 6 wherein the antifungal drug is selected from the group consisting of miconazole, ketoconazole, itraconazole, pharmaceutically acceptable salts thereof and
stereoisomers thereof.

10. The method of Claim 1 wherein the compound of Formula (I) is N-acetyl-l-cysteine or cysteine and the antifungal drug is itraconazole.

5 11. The method of Claim 1 wherein the compound of Formula (I), urea and antifungal drug are administered to the nail under occlusive conditions.

10 12. The method of Claim 2 wherein the compound of Formula (I), urea and antifungal drug are administered to the nail under occlusive conditions.

15 13. The method of Claim 3 wherein the compound of Formula (I), urea and antifungal drug are administered to the nail under occlusive conditions.

20 14. The method of Claim 4 wherein the compound of Formula (I), urea and antifungal drug are administered to the nail under occlusive conditions.

15. The method of Claim 5 wherein the compound of Formula (I), urea and antifungal drug are administered to the nail under occlusive conditions.

25 16. The method of Claim 6 wherein the compound of Formula (I), urea and antifungal drug are administered to the nail under occlusive conditions.


30 17. The method of Claim 7 wherein the compound of Formula (I), urea and antifungal drug are administered to the nail under occlusive conditions.

35 18. The method of Claim 8 wherein the compound of Formula (I), urea and antifungal drug are administered to the nail under occlusive conditions.

19. The method of Claim 9 wherein the compound of Formula (I), urea and antifungal drug are administered to the nail under occlusive conditions.

5 20. The method of Claim 10 wherein the compound of Formula (I), urea and antifungal drug are administered to the nail under occlusive conditions.

10 21. A bandage adapted for the topical administration of medication to the nail, said bandage comprising a T-shaped adhesive backing, and a flexible pad having an impervious backing and a nail-shaped cavity backed by said impervious backing, wherein said nail-shaped cavity contains absorptive means having absorbed therein urea and a compound of Formula 15 (I) :



20

the pharmaceutically acceptable salts or esters thereof, and stereoisomers thereof,

wherein:

25

$\text{R} = \text{H, CONHCH}_2\text{COOH, NH}_2$ or COOR^2 wherein R^2 is H or $\text{C}_{1-4}\text{alkyl}$;

$\text{R}^1 = \text{H, COCH}_3$, CONH_2 , or $\text{CO}(\text{CH}_2)_m\text{CH}(\text{NH}_2)(\text{COOH})$ wherein m is 1 or 2; and


30

$n =$ a number having a value of from 1 to 4.

35

22. The bandage of Claim 21 wherein the urea and compound of Formula (I) contained in said absorptive means are anhydrous.

23. A composition comprising (1) a compound represented by Formula (I):



5 the pharmaceutically acceptable salts or esters thereof,
and stereoisomers thereof,

wherein:

10 R = H, CONHCH₂COOH, NH₂ or COOR² wherein R² is H or C₁₋₄alkyl;

R¹ = H, COCH₃, CONH₂, or CO(CH₂)_mCH(NH₂)(COOH) wherein m is
1 or 2; and

15 n = a number having a value of from 1 to 4; and

(2) urea; and

(3) an effective amount of an antifungal drug, (1) and (2)
20 being present in an amount sufficient to enhance the permeation
of said antifungal drug through nail tissue.

24. The composition of Claim 23 wherein the compound
represented by Formula (I) is selected from the group consisting
25 of l-cysteine, cysteine, d-cysteine, dl-cysteine, N-acetyl-l-
cysteine, dl-homocysteine, l-cysteine methyl ester, l-cysteine
ethyl ester, N-carbamoyl cysteine, glutathione and cysteamine.

25. The composition of Claim 24 wherein the compound
30 represented by Formula (I) is N-acetyl-l-cysteine or cysteine.

26. The composition of Claim 23 wherein the antifungal
drug is selected from the group consisting of miconazole,
ketoconazole, itraconazole, fluconazole, econazole, terconazole,
35 saperconazole, amorolfine, ciclopirox, oxiconazole, clotrim-
azole, terbinafine, naftifine, pharmaceutically acceptable salts
thereof and stereoisomers thereof.

27. The composition of Claim 24 wherein the antifungal drug is selected from the group consisting of miconazole, ketoconazole, itraconazole, fluconazole, econazole, terconazole, saperconazole, amorolfine, ciclopirox, oxiconazole, clotrimazole, terbinafine, naftifine, pharmaceutically acceptable salts thereof and stereoisomers thereof.

28. The composition of Claim 25 wherein the antifungal drug is selected from the group consisting of miconazole, ketoconazole, itraconazole, fluconazole, econazole, terconazole, saperconazole, amorolfine, ciclopirox, oxiconazole, clotrimazole, terbinafine, naftifine, pharmaceutically acceptable salts thereof and stereoisomers thereof.

29. The composition of Claim 26 wherein the antifungal drug is selected from the group consisting of miconazole, ketoconazole, itraconazole, pharmaceutically acceptable salts thereof and stereoisomers thereof.

30. The composition of Claim 27 wherein the antifungal drug is selected from the group consisting of miconazole, ketoconazole, itraconazole, pharmaceutically acceptable salts thereof and stereoisomers thereof.

31. The composition of Claim 28 wherein the antifungal drug is selected from the group consisting of miconazole, ketoconazole, itraconazole, pharmaceutically acceptable salts thereof and stereoisomers thereof.

32. The composition of Claim 23 wherein the compound of Formula (I) is N-acetyl-L-cysteine or cysteine and the antifungal drug is itraconazole.


33. The composition of Claim 23 wherein said composition contains propylene carbonate and propylene glycol.

34. The composition of Claim 33 wherein the anti-fungal compound is itraconazole.

35. A composition comprising propylene carbonate,
5 propylene glycol and an anti-fungal drug.


36. The composition of Claim 35 wherein the anti-fungal drug is selected from the group consisting of miconazole, ketoconazole, itraconazole, pharmaceutically acceptable salts
10 thereof and stereoisomers thereof.

37. The composition of Claim 36 wherein the anti-fungal drug is itraconazole.




0 2 / 1 7

FIG. 2




0 3 / 1 7

FIG. 3a




0 4 / 1 7

FIG. 3b




0 5 / 1 7

FIG. 4a




0 6 / 1 7

FIG. 4b



07 / 17

FIG. 5a

0 8 / 1 7

FIG. 5b




FIG. 6a




FIG. 6b







FIG. 13A**FIG. 13B****FIG. 13C**

12 / 17

FIG. 7






FIG. 8




14 / 17

FIG. 9

ITRACONAZOLE PERMEATION THROUGH NAIL
(N=3, AVG + STD)


15 / 17

FIG. 10




16 / 17

FIG. 11



17 / 17

FIG. 12



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/15729

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 7/043, 9/70, 31/095
US CL : 514/399, 562, 588, 946, 947, 953

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/399, 562, 588, 946, 947, 953

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS

search terms: nail, cysteine, acetyl cysteine, urea, maculat?, miconazole, ketoconazole, itraconazole, oxiconazole

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 5,181,914 (ZOOK) 26 January 1993, abstract.	1-37
Y	US, A, 4,672,078 (SAKAI ET AL.) 09 June 1987, column 1, lines 16-25.	1-37
Y	EP, A, 0,440,298 (VAN DEN HOVEN ET AL.) 07 August 1991, abstract and page 3.	1-37

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
29 JANUARY 1996	13 FEB 1996
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer BRIAN M. BURN <i>Deborah Frane /07</i>
Facsimile No. (703) 305-3230	Telephone No. (703) 308-1235